9月10日 - ** Hims & Hers Health HIMS.N股价盘前上涨2.2%至48.76美元
** 据彭博新闻社周二晚些时候报道，该公司计划推出针对男性睾酮低下患者的产品
** 报道称，HIMS将首先推出复方制剂 "埃洛米芬"（enclomiphene），这是一种在标签外用于治疗男性睾酮低下的药物。
** HIMS 此前曾表示，作为未来几年发展战略的一部分，公司计划拓展睾酮和更年期治疗领域。
** 截至上次收盘，股价累计上涨 97.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.